Asset Management One Co. Ltd. Has $19.53 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Asset Management One Co. Ltd. raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 243,375 shares of the medical device company’s stock after purchasing an additional 7,901 shares during the quarter. Asset Management One Co. Ltd. owned 0.06% of DexCom worth $19,528,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. MFG Wealth Management Inc. bought a new stake in shares of DexCom in the 4th quarter worth approximately $1,574,000. Van ECK Associates Corp raised its stake in shares of DexCom by 325.0% in the 4th quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company’s stock valued at $6,674,000 after buying an additional 65,622 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of DexCom by 28.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company’s stock worth $4,596,000 after acquiring an additional 13,111 shares during the period. Peterson Wealth Services boosted its position in shares of DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after acquiring an additional 201 shares in the last quarter. Finally, Essex Financial Services Inc. raised its position in DexCom by 3.3% in the fourth quarter. Essex Financial Services Inc. now owns 9,617 shares of the medical device company’s stock worth $748,000 after purchasing an additional 303 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by corporate insiders.

DexCom Price Performance

DXCM opened at $89.07 on Friday. The stock has a market cap of $34.79 billion, a P/E ratio of 53.34, a P/E/G ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a fifty day simple moving average of $82.44 and a 200 day simple moving average of $75.44.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. On average, research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on DXCM shares. Royal Bank of Canada dropped their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.